The Gastric Cancer Therapy Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Disease (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Others), By Treatment (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery), By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Specialty and Retail Pharmacies, Others, Hospital Pharmacies).
In 2024, the landscape of gastric cancer therapy continues to evolve with advancements in precision medicine and immunotherapy. Novel targeted therapies, such as HER2 inhibitors and immune checkpoint inhibitors, have emerged as promising treatment options, particularly for patients with advanced or metastatic disease. Additionally, ongoing research into the molecular subtypes of gastric cancer has enabled the development of personalized treatment approaches tailored to individual patients' tumor characteristics. With a growing emphasis on multidisciplinary care and early detection strategies, the prognosis for gastric cancer patients is gradually improving.
A significant trend in the gastric cancer therapy market is the rapid advancement of personalized medicine and targeted therapies. With a deeper understanding of the molecular mechanisms driving gastric cancer progression, there's a shift towards developing tailored treatment approaches that specifically target the unique genetic makeup of individual tumors. This trend is fueled by innovations in genomic sequencing technologies, biomarker identification, and precision medicine, allowing for more precise diagnosis and treatment selection, ultimately improving patient outcomes and survival rates.
The primary driver propelling the gastric cancer therapy market is the escalating burden of gastric cancer incidence globally. As one of the most common and lethal malignancies worldwide, gastric cancer poses a significant public health challenge, particularly in regions with high prevalence rates such as Eastern Asia, Central and Eastern Europe, and parts of South America. The rising incidence rates, coupled with the limited effectiveness of conventional therapies, are driving the urgent need for innovative treatment options, spurring research and development efforts in the field of gastric cancer therapy.
An untapped opportunity within the gastric cancer therapy market lies in the integration of immunotherapy and combination therapies to enhance treatment efficacy. Immunotherapy, particularly immune checkpoint inhibitors, has emerged as a promising approach in cancer treatment, including gastric cancer. Leveraging the synergistic effects of combining immunotherapy with other modalities such as chemotherapy, targeted therapy, and radiation therapy presents a significant opportunity to improve response rates and long-term outcomes for patients with gastric cancer. Additionally, exploring novel immunotherapeutic targets and predictive biomarkers can further optimize treatment strategies and expand the therapeutic landscape in gastric cancer therapy.
The Immunotherapy Treatment segment within the Gastric Cancer Therapy Market is experiencing rapid growth due to several factors driving the demand for innovative and targeted cancer treatments and the increasing adoption of immunotherapy as a standard of care in gastric cancer management. Gastric cancer, a heterogeneous malignancy affecting the stomach lining, encompasses various subtypes, including adenocarcinoma, lymphoma, gastrointestinal stromal tumor (GIST), carcinoid tumor, and others, each with distinct molecular profiles and treatment challenges. Immunotherapy, a form of cancer treatment that harnesses the body's immune system to recognize and destroy cancer cells, has emerged as a promising therapeutic approach for gastric cancer patients, particularly those with advanced or metastatic disease. Immunotherapeutic agents such as programmed cell death protein 1 (PD-1) inhibitors, programmed death-ligand 1 (PD-L1) inhibitors, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors work by blocking immune checkpoint pathways that inhibit T-cell-mediated antitumor immune responses, thereby enhancing immune surveillance and antitumor immunity in gastric cancer patients. With the growing understanding of the immune evasion mechanisms employed by gastric tumors and the identification of biomarkers predictive of immunotherapy response, there is increasing interest in integrating immunotherapeutic agents into standard treatment regimens for gastric cancer across different disease stages and molecular subtypes. Immunotherapy offers advantages such as durable responses, manageable toxicity profiles, and potential synergies with other treatment modalities such as chemotherapy, targeted therapy, and radiation therapy, making it a valuable addition to the therapeutic armamentarium for gastric cancer. Additionally, the availability of oral and injectable formulations of immunotherapeutic agents and their distribution through specialty and retail pharmacies, hospital pharmacies, and other healthcare settings contribute to the accessibility and convenience of immunotherapy for gastric cancer patients. As oncologists, gastroenterologists, and multidisciplinary cancer care teams increasingly recognize the clinical benefits and therapeutic potential of immunotherapy in improving outcomes and survival in gastric cancer patients, the Immunotherapy Treatment segment is poised for significant growth in the Gastric Cancer Therapy Market, offering novel and personalized treatment options for this challenging malignancy.
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAmgen Inc, AstraZeneca Plc, Bristol-Myers Squibb Company, Celltrion Healthcare Co. Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Imugene Ltd, Merck & Co. Inc, Novartis AG, Otsuka Holdings Co. Ltd, Pfizer Inc, Sanofi S.A
By Disease
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Others
By Treatment
Immunotherapy
Targeted Therapy
Chemotherapy
Radiation Therapy and Surgery
By Drug Class
PD-1/PD-L1 Inhibitors
HER2 Antagonists
VEGFR2 Antagonists
Others
By Route of Administration
Oral
Injectable
By Distribution Channel
Specialty and Retail Pharmacies
Others
Hospital Pharmacies
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Amgen Inc
AstraZeneca Plc
Bristol-Myers Squibb Company
Celltrion Healthcare Co. Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Imugene Ltd
Merck & Co. Inc
Novartis AG
Otsuka Holdings Co. Ltd
Pfizer Inc
Sanofi S.A
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Gastric Cancer Therapy Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Gastric Cancer Therapy Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Gastric Cancer Therapy Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Gastric Cancer Therapy Market Size Outlook, $ Million, 2021 to 2030
3.2 Gastric Cancer Therapy Market Outlook by Type, $ Million, 2021 to 2030
3.3 Gastric Cancer Therapy Market Outlook by Product, $ Million, 2021 to 2030
3.4 Gastric Cancer Therapy Market Outlook by Application, $ Million, 2021 to 2030
3.5 Gastric Cancer Therapy Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Gastric Cancer Therapy Industry
4.2 Key Market Trends in Gastric Cancer Therapy Industry
4.3 Potential Opportunities in Gastric Cancer Therapy Industry
4.4 Key Challenges in Gastric Cancer Therapy Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Gastric Cancer Therapy Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Gastric Cancer Therapy Market Outlook by Segments
7.1 Gastric Cancer Therapy Market Outlook by Segments, $ Million, 2021- 2030
By Disease
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Others
By Treatment
Immunotherapy
Targeted Therapy
Chemotherapy
Radiation Therapy and Surgery
By Drug Class
PD-1/PD-L1 Inhibitors
HER2 Antagonists
VEGFR2 Antagonists
Others
By Route of Administration
Oral
Injectable
By Distribution Channel
Specialty and Retail Pharmacies
Others
Hospital Pharmacies
8 North America Gastric Cancer Therapy Market Analysis and Outlook To 2030
8.1 Introduction to North America Gastric Cancer Therapy Markets in 2024
8.2 North America Gastric Cancer Therapy Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Gastric Cancer Therapy Market size Outlook by Segments, 2021-2030
By Disease
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Others
By Treatment
Immunotherapy
Targeted Therapy
Chemotherapy
Radiation Therapy and Surgery
By Drug Class
PD-1/PD-L1 Inhibitors
HER2 Antagonists
VEGFR2 Antagonists
Others
By Route of Administration
Oral
Injectable
By Distribution Channel
Specialty and Retail Pharmacies
Others
Hospital Pharmacies
9 Europe Gastric Cancer Therapy Market Analysis and Outlook To 2030
9.1 Introduction to Europe Gastric Cancer Therapy Markets in 2024
9.2 Europe Gastric Cancer Therapy Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Gastric Cancer Therapy Market Size Outlook by Segments, 2021-2030
By Disease
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Others
By Treatment
Immunotherapy
Targeted Therapy
Chemotherapy
Radiation Therapy and Surgery
By Drug Class
PD-1/PD-L1 Inhibitors
HER2 Antagonists
VEGFR2 Antagonists
Others
By Route of Administration
Oral
Injectable
By Distribution Channel
Specialty and Retail Pharmacies
Others
Hospital Pharmacies
10 Asia Pacific Gastric Cancer Therapy Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Gastric Cancer Therapy Markets in 2024
10.2 Asia Pacific Gastric Cancer Therapy Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Gastric Cancer Therapy Market size Outlook by Segments, 2021-2030
By Disease
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Others
By Treatment
Immunotherapy
Targeted Therapy
Chemotherapy
Radiation Therapy and Surgery
By Drug Class
PD-1/PD-L1 Inhibitors
HER2 Antagonists
VEGFR2 Antagonists
Others
By Route of Administration
Oral
Injectable
By Distribution Channel
Specialty and Retail Pharmacies
Others
Hospital Pharmacies
11 South America Gastric Cancer Therapy Market Analysis and Outlook To 2030
11.1 Introduction to South America Gastric Cancer Therapy Markets in 2024
11.2 South America Gastric Cancer Therapy Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Gastric Cancer Therapy Market size Outlook by Segments, 2021-2030
By Disease
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Others
By Treatment
Immunotherapy
Targeted Therapy
Chemotherapy
Radiation Therapy and Surgery
By Drug Class
PD-1/PD-L1 Inhibitors
HER2 Antagonists
VEGFR2 Antagonists
Others
By Route of Administration
Oral
Injectable
By Distribution Channel
Specialty and Retail Pharmacies
Others
Hospital Pharmacies
12 Middle East and Africa Gastric Cancer Therapy Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Gastric Cancer Therapy Markets in 2024
12.2 Middle East and Africa Gastric Cancer Therapy Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Gastric Cancer Therapy Market size Outlook by Segments, 2021-2030
By Disease
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Others
By Treatment
Immunotherapy
Targeted Therapy
Chemotherapy
Radiation Therapy and Surgery
By Drug Class
PD-1/PD-L1 Inhibitors
HER2 Antagonists
VEGFR2 Antagonists
Others
By Route of Administration
Oral
Injectable
By Distribution Channel
Specialty and Retail Pharmacies
Others
Hospital Pharmacies
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Amgen Inc
AstraZeneca Plc
Bristol-Myers Squibb Company
Celltrion Healthcare Co. Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline plc
Imugene Ltd
Merck & Co. Inc
Novartis AG
Otsuka Holdings Co. Ltd
Pfizer Inc
Sanofi S.A
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Disease
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Others
By Treatment
Immunotherapy
Targeted Therapy
Chemotherapy
Radiation Therapy and Surgery
By Drug Class
PD-1/PD-L1 Inhibitors
HER2 Antagonists
VEGFR2 Antagonists
Others
By Route of Administration
Oral
Injectable
By Distribution Channel
Specialty and Retail Pharmacies
Others
Hospital Pharmacies
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
The global Gastric Cancer Therapy Market is one of the lucrative growth markets, poised to register a 16.3% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Amgen Inc, AstraZeneca Plc, Bristol-Myers Squibb Company, Celltrion Healthcare Co. Ltd, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Imugene Ltd, Merck & Co. Inc, Novartis AG, Otsuka Holdings Co. Ltd, Pfizer Inc, Sanofi S.A
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume